TTC39B antibody (AA 129-682)

Catalog No. ABIN7870445

This Rabbit Polyclonal antibody specifically detects TTC39B in WB, ELISA and FACS. It exhibits reactivity toward Human, Mouse and Rat.

Quick Overview for TTC39B antibody (AA 129-682) (ABIN7870445)

Target: TTC39B (Tetratricopeptide Repeat Domain 39B (TTC39B))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This TTC39B antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Product Details anti-TTC39B Antibody

Binding Specificity: AA 129-682

Purpose: TTC39B Antibody / C9orf52

Purification: Antigen affinity purified

Immunogen: E. coli-derived recombinant human protein (amino acids K129-D682) was used as the immunogen for the TTC39B antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the TTC39B antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the TTC39B antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for TTC39B

Target: TTC39B (Tetratricopeptide Repeat Domain 39B (TTC39B))

Alternative Name: TTC39B

Background: Tetratricopeptide repeat protein 39B is a protein that in humans is encoded by the TTC39B gene. TTC39B protein contains two TPR repeats (aa 39 3-426 and 626 -659). TCC39B protein is the product of a high density lipoprotein (HDL) gene that promotes the ubiquitination and degradation of liver X receptor (LXR). TTC39B null or deficient mice challenged with high fat/cholesterol/bile salt diet exhibit increased LX R protein and target gene expression. TTC39B deficiency is reported to stabilize LXR by reducing its polyubiquitination and proteasomal degradation. Hence it reduces the incidence of atherosclerosis and steatohepatitis. TTC39B deficiency mice display higher levels of HDL and Apoplipoprotein A-1 and lower levels of hepatic triglyceride synthesis.However it does not affect glucose tolerance or hepatic gluconeogenesis.

UniProt: Q5VTQ0